ReviewCorrelates of GLA family adjuvants’ activities

Add time:09/03/2019    Source:sciencedirect.com

Lipopolysaccharide (LPS) is a well-defined agonist of Toll-like receptor (TLR) 4 that activates innate immune responses and influences the development of the adaptive response during infection with Gram-negative bacteria. Many years ago, Dr. Edgar Ribi separated the adjuvant activity of LPS from its toxic effects, an effort that led to the development of monophosphoryl lipid A (MPL). MPL, derived from Salmonella minnesota R595, has progressed through clinical development and is now used in various product-enabling formulations to support the generation of antigen-specific responses in several commercial and preclinical vaccines. We have generated several synthetic lipid A molecules, foremost glucopyranosyl lipid adjuvant (GLA) and second-generation lipid adjuvant (SLA), and have advanced these to clinical trial for various indications. In this review we summarize the potential and current positioning of TLR4-based adjuvant formulations in approved and emerging vaccines.

We also recommend Trading Suppliers and Manufacturers of GLA 60 (cas 111247-04-2). Pls Click Website Link as below: cas 111247-04-2 suppliers

Prev:Practical stereoselective synthesis of α-linked C-glucosamine propionic acid esters: conversion to GLA-60 derivatives
Next:Research papersStructure and tumor necrosis factor-inducing activity of dispersed particles of a lipid A analogue, GLA-60, and phosphatidylcholine mixture)